ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,877 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselTargImmune Therapeutics AG
TargImmune Therapeutics AG Logo
Verified· 3 sources

TargImmune Therapeutics AG

Summary

About the company

The core activity of TargImmune Therapeutics AG is the development and research of oncological compounds and the development of a modular, synthetic, targeted platform technology for nucleic acid therapy. In particular, the company focuses on the development of targeted apoptosis and immunomodulators (TAIMs) that use synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly to the target. The goal is to selectively destroy cancer cells by mimicking natural processes.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered2
Targeted nucleic acid delivery platform (TAIMs)
Targeted nucleic acid delivery platform using synthetic nanoparticles to deliver interchangeable nucleic acid therapeutics directly on target; developed as targeted apoptosis and immune modulators for cancer and other therapy areas.
Oncology agents (TAR001, TAR002, TAR003)
Oncology drug programs based on the TAIM platform, initially focused on three receptor targets; lead compound TAR001 delivers dsRNA to targeted cancer cells and is being developed for multiple solid tumours.
Press

Media

March 20, 2025Media
TargImmune Therapeutics gets acquired
startupticker.ch

Knowledge

No knowledge articles yet

Once TargImmune Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

TargImmune Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank TargImmune Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of TargImmune Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

St. Alban-Anlage 70
4052 Basel

At a glance

Legal form
Corporation
UID
CHE-349.430.797
Founded
2024 · 2 years
Last commercial register change
June 12, 2026
Employees
1 to 10

Similar companies

AB
Amyra Biotech AG
Basel
CT
CORETAG Therapeutics AG
Basel
RS
Regeneron Switzerland GmbH
Basel
AS
Autolus Switzerland AG
Basel